Moderna's mRNA vaccine approved by FDA

Key Points:

• The FDA has approved Moderna’s mFLUSIVA, the first mRNA-based flu vaccine, for adults aged 50 and older, marking a significant advancement in influenza prevention using mRNA technology similar to COVID-19 vaccines.
• Clinical trials involving over 40,000 participants demonstrated that mFLUSIVA is approximately 27% more effective than standard-dose flu vaccines in preventing lab-confirmed influenza, with accelerated approval granted for adults 65 and older.
• mRNA flu vaccines can be produced faster than traditional egg-based vaccines, potentially improving the match to rapidly evolving flu virus strains and addressing the perennial issue of vaccine-virus mismatch.
• Experts emphasize that mFLUSIVA should be considered an additional option rather than a replacement for existing flu vaccines, and they advise individuals to consult healthcare professionals to determine the most suitable vaccine.
• Common side effects reported include headache, fatigue, muscle and joint pain, nausea, and injection site reactions, with rare cases of severe allergic reactions; precautions are recommended for those with prior vaccine allergies or certain medical conditions.